Xadago is a selective, reversible MAO-B inhibitor that also inhibits release of glutamate. MAO-B inhibitors help prevent the breakdown of dopamine in the brain. Xadago is a novel reversible MAO-B inhibitor proposed as an adjunctive therapy to prolong “on” time in patients whose primary Parkinson disease therapy is not working well.

If you have a Hayes login, click here to view the full report on the Knowledge Center.